ライフサイエンスコーパス: proton pump inhibitor

1 cidifying the cytosol with bafilomycin A1, a proton pump inhibitor.

2 Testing was performed on maintenance proton pump inhibitor.

3 re, with four (21%) of 19 patients needing a proton-pump inhibitor.

4 asibility before and after administration of proton pump inhibitors.

5 long-term history of diarrhea, responsive to proton pump inhibitors.

6 tions were similar when we excluded users of proton pump inhibitors.

7 but the survival benefit of 0.0167% favored proton pump inhibitors.

8 crine tumors, is elevated in patients taking proton pump inhibitors.

9 ed VHs that were induced or enhanced by oral proton pump inhibitors.

10 Medical management of GERD mainly uses proton pump inhibitors.

11 C. difficile-associated diarrhea with use of proton pump inhibitors.

12 onomic problem, due to the widespread use of proton pump inhibitors.

13 patients requiring maintenance therapy with proton pump inhibitors.

14 tandard treatment of H2 receptor blockers or proton pump inhibitors.

15 id rebound observed after discontinuation of proton pump inhibitors.

16 scenario, considering the widespread use of proton pump inhibitors.

17 that esophageal eosinophilia can respond to proton pump inhibitors.

18 neric-equivalent beta-blockers, statins, and proton-pump inhibitors.

19 essed at baseline while they were not taking proton-pump inhibitors.

20 Patterns were similar for ACE inhibitors and proton-pump inhibitors.

21 and reminders to reduce inappropriate use of proton-pump inhibitors.

22 hese patients were successfully treated with proton-pump inhibitors.

23 ntestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limita

24 Results for proton-pump inhibitors (2.1 percentage points [CI, -3.7

25 -2 receptor antagonists (63.9%), followed by proton pump inhibitors (23.1%), and sucralfate (12.2%).

26 High dose intravenous proton pump inhibitor after endoscopic therapy for pepti

27 he clinical efficacy of oral and intravenous proton pump inhibitor after endoscopic therapy.

28 d received either 10-day sequential therapy (Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days a

29 sociated diarrhea, although judicious use of proton pump inhibitors and antibiotics, emphasis on hand

30 (27%-66%) reduction for concurrent users of proton pump inhibitors and coxibs.

31 nocarcinoma coincided with popularization of proton pump inhibitors and has focused attention on gast

32 There were no differences between proton pump inhibitors and histamine 2 receptor antagoni

33 phylaxis, review the comparative efficacy of proton pump inhibitors and histamine 2 receptor antagoni

34 olone use; there is also an association with proton pump inhibitors and increased recognition of case

35 The introduction of new drugs, including proton pump inhibitors and innovative endoscopic and sur

36 BACKGROUND& AIMS: Proton pump inhibitors and nonsteroidal anti-inflammator

37 MI patterns before and after treatment with proton pump inhibitors and to compare the performance of

38 Using full-dose proton-pump inhibitor and high-dose Metronidazole in gro

39 Using full-dose proton-pump inhibitor and higher doses of Metronidazole

40 dose Metronidazole in group A, and full-dose proton-pump inhibitor and prescription from a Gastroente

41 Ds, while 18% was associated with the use of proton-pump inhibitors and 14% with the use of less toxi

42 parietal cell proton pump and development of proton pump inhibitors, and (3) identification of Helico

43 y-eight percent of Stretta patients were off proton pump inhibitors, and an additional 31% had reduce

44 , change in body mass index, smoking, use of proton pump inhibitors, and anti-diabetic medications, a

45 Lifestyle modifications, proton pump inhibitors, and laparoscopic fundoplication

46 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, and Nissen fundoplication.

47 iotensin-converting-enzyme (ACE) inhibitors, proton-pump inhibitors, and 3-hydroxy-3-methylglutaryl c

48 idemic agents, antidepressants, prescription proton-pump inhibitors, and muscle relaxants.

49 py and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4) patients receiving follow-

50 nce interval (CI): 2.1, 5.0), current use of proton pump-inhibitor antiheartburn medications (OR = 6.

51 r histamine 2 receptor antagonists; however, proton pump inhibitors appear to be the dominant drug cl

52 Whether proton pump inhibitors are more effective than histamine

53 Intravenous proton pump inhibitors are more potent and longer-acting

54 that, although both can raise the pH to >4, proton pump inhibitors are much more likely to maintain

55 Although studies implicate proton pump inhibitors as a risk for CDI, the magnitude

56 as to assess the efficacy of pantoprazole, a proton pump inhibitor, as an adjunct to elective EVL.

57 50% treatment-experienced, and 30% receiving proton pump inhibitors at start of treatment.

58 and a 50% or greater reduction in the use of proton-pump inhibitors at 1 year.

59 ation of intravenous pantoprazole, the first proton pump inhibitor available by this route in the Uni

60 impact on phagosome permeabilization of the proton pump inhibitor bafilomycin A.

61 n effect that was inhibited by the lysosomal proton pump inhibitor, bafilomycin A1.

62 Standard proton-pump inhibitor-based therapy for Helicobacter pyl

63 ibitor, the micromotors can function without proton pump inhibitors because of their built-in proton

64 of peptic ulcer without co-prescription of a proton-pump inhibitor; beta blockers prescribed to those

65 9% to 48% of patients, and increasing use of proton-pump inhibitors, but not with change in age, NSAI

66 Whether oral proton pump inhibitor can replace intravenous proton pum

67 Unlike histamine-2-receptor antagonists, proton pump inhibitors can elevate and maintain the intr

68 hibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronid

69 Proton pump inhibitors, commonly used for gastric acid s

70 reased, reflux symptoms improved, and use of proton-pump inhibitors decreased.

71 Proton pump inhibitors defend the mucosa from injury by

72 interactions with H2-receptor antagonists or proton pump inhibitors, does not cause central nervous s

73 udies, between high-dose or long-term use of proton pump inhibitor drugs and certain possibly attribu

74 Hypergastrinemia, induced by proton pump inhibitors, enhances expression of cyclooxyg

75 The adjusted odds ratio for > or =5 years of proton pump inhibitor exposure was 1.1 (95% confidence i

76 Histamine receptor-2 antagonist or proton pump inhibitor for 9 days of stress ulcer prophyl

77 Concurrent users of NSAIDs and proton pump inhibitors had a 54% (27%-72%) risk reductio

78 The pharmacodynamic efficacy of proton pump inhibitors has not been specifically evaluat

79 eatment using tetracycline, furazolidone and proton-pump inhibitors has been effective and low cost i

80 Patients receiving oral proton pump inhibitor have a shorter hospital stay.

81 ived as appropriate initial agents, although proton pump inhibitors have become first-line therapy in

82 Proton pump inhibitors have been demonstrated to be the

83 Statins and proton pump inhibitors have been shown to decrease adver

84 While proton pump inhibitors have been widely used for blockin

85 Proton pump inhibitors have not been assessed in a direc

86 e macular degeneration patients treated with proton pump inhibitors having the core structure, 2-pyri

87 eoxycholic acid, and the addition of an oral proton-pump inhibitor improved weight gain and survival.

88 , but it is not known whether treatment with proton pump inhibitors improves asthma control.

89 roton pump inhibitor can replace intravenous proton pump inhibitor in this setting is unknown.

90 ating the efficacy and safety of withholding proton pump inhibitors in critically ill patients.

91 arrett esophagus; (4) efficacy and safety of proton pump inhibitors in GERD; and (5) the mechanism fo

92 ctions produced by an ablation procedure and proton pump inhibitors in incompletely ablated Barrett's

93 ial does indicate the promise of intravenous proton pump inhibitors in reducing upper gastrointestina

94 The use of proton pump inhibitors in this setting also may have a p

95 Bafilomycin A1, a lysosomal proton pump inhibitor, increases mature GFP-CFTR, confir

96 onducted trials indicate that an intravenous proton pump inhibitor is significantly more effective th

97 Empiric trial using proton pump inhibitors is still the recommended initial

98 rs, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors is unknown.

99 therefore coadministration of aspirin with a proton-pump inhibitor is an attractive option and is und

100 to tailor therapy, but an empiric trial of a proton pump inhibitor may be an alternative diagnostic a

101 xis, intermittent dosing with an intravenous proton pump inhibitor may be an alternative to high-dose

102 t that dipeptidyl peptidase-4 inhibitors and proton-pump inhibitors might enhance beta-cell survival

103 es, a reduction of 50% or more in the use of proton-pump inhibitors occurred in 93% of patients, and

104 eflux disease who have a partial response to proton-pump inhibitors often seek alternative therapy.

105 This cleavage was blocked by the proton pump inhibitor omeprazole and mediated by the aci

106 in complex with a human drug substrate, the proton pump inhibitor omeprazole.

107 clinical trials that assessed the effect of proton pump inhibitors on healing of erosive esophagitis

108 per gastrointestinal bleeding; the effect of proton pump inhibitors on ventilator-associated pneumoni

109 ts of lansoprazole (LANZO) administration, a proton pump inhibitor, on the dystrophic muscle phenotyp

110 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, open fundoplication, and laparos

111 le therapy with two antibiotics and either a proton pump inhibitor or bismuth is the regimens of choi

112 s) are use of a coxib or concurrent use of a proton pump inhibitor or double-dose histamine-2 recepto

113 dication was defined as a combination use of proton pump inhibitor or H2 receptor blockers, plus clar

114 ally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonis

115 ux, defined as use of antireflux medication (proton pump inhibitors or histamine2 receptor antagonist

116 of the three trials, 124 (51%) were taking a proton-pump inhibitor or H2 blocker at enrolment.

117 edication use was defined as any order for a proton-pump inhibitor or histamine(2) receptor antagonis

118 use was defined as any pharmacy charge for a proton-pump inhibitor or histamine-2 receptor antagonist

119 p) in patients who were and were not using a proton-pump inhibitor or histamine-receptor-2 (H2) block

120 The association was significant for proton-pump inhibitors (OR = 2.7, 95% CI = 1.4-5.4), but

121 The association was significant for proton-pump inhibitors (OR, 1.3; 95% CI, 1.1-1.4) but no

122 ot clearly support lower bleeding rates with proton pump inhibitors over histamine 2 receptor antagon

123 The proton pump inhibitor, pantoprazole, is unique in that i

124 gests that standard three-drug regimens of a proton-pump inhibitor plus amoxicillin and clarithromyci

125 ion regarding the safety of co-prescribing a proton pump inhibitor (PPI) and clopidogrel.

126 (OR 2.43(2.06-2.88) and 1.90 (1.68-2.14) for proton pump inhibitor (PPI) and histamine 2 receptor ant

127 Outcome in proton pump inhibitor (PPI) and non-PPI users was classi

128 Observational studies linking proton pump inhibitor (PPI) exposure with community-acqu

129 t in vitro and animal studies have found the proton pump inhibitor (PPI) lansoprazole to be highly ac

130 esponse (SVR) included age, race, cirrhosis, proton pump inhibitor (PPI) prescription, prior HCV trea

131 Esophageal eosinophilia can be proton pump inhibitor (PPI) resistant or responsive, rep

132 ficance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosin

133 analysis of adjunctive oral and intravenous proton pump inhibitor (PPI) therapies for patients with

134 ageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders)

135 RD) commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary li

136 any patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to expe

137 Inadequate response to proton pump inhibitor (PPI) therapy in patients with gas

138 Intravenous bolus plus infusion proton pump inhibitor (PPI) therapy is recommended for p

139 This study assessed the effect of proton pump inhibitor (PPI) therapy on the volume, distr

140 Partial response to proton pump inhibitor (PPI) therapy poses a healthcare c

141 with symptomatic GERD requiring maintenance proton pump inhibitor (PPI) therapy were entered into a

142 Demographics, duration of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related

143 some patients whose symptoms persist despite proton pump inhibitor (PPI) therapy.

144 referral of TS, in patients without previous proton pump inhibitor (PPI) treatment and in patients on

145 : Studies have reported associations between proton pump inhibitor (PPI) use and dementia.

146 were hospitalized and they had higher MELD, proton pump inhibitor (PPI) use and HE without differenc

147 0.13), perioperative outcome, regurgitation, proton pump inhibitor (PPI) use, lower esophageal sphinc

148 On the second day of investigation, proton pump inhibitor (PPI) was given at a mean dose of

149 GERD patients who were being treated with a proton pump inhibitor (PPI), 50% had pathologic esophage

150 k course eradication therapy consisting of a proton pump inhibitor (PPI), amoxicillin, and clarithrom

151 When erlotinib is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which

152 the value of skin tests in the diagnosis of proton pump inhibitor (PPI)-induced hypersensitivity rea

153 Between 1997 and 1999, 177 patients with proton pump inhibitor (PPI)-refractory GERD were randomi

154 igation is required in the assessment of the proton pump inhibitor (PPI)-refractory patient.

155 tidyl peptidase IV inhibitor (DPP-4i), and a proton pump inhibitor (PPI).

156 drug (NSAID(NS)) alone; 2) NSAID(NS) plus a proton pump inhibitor (PPI); and 3) a cyclooxygenase 2-s

157 BACKGROUND & AIMS: Proton pump inhibitors (PPI) are among the top 10 most p

158 BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with a

159 armacokinetic studies have demonstrated that proton pump inhibitors (PPI) reduce exposure of mycophen

160 temic treatment of B16-OVA-bearing mice with proton pump inhibitors (PPI) significantly increased the

161 The association between proton pump inhibitors (PPI) use and risk of acute inter

162 (NMA) was conducted to compare the different proton pump inhibitors (PPI) within triple therapy.

163 Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti-inflamma

164 omes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and to evaluate dura

165 nic hepatitis C virus (HCV) are on prolonged proton-pump inhibitor (PPI) therapy and wish to remain o

166 ds ratios (ORs) were calculated for GORD and proton-pump inhibitor (PPI) use in hormone and non-hormo

167 Many studies have shown that high-dose proton-pumps inhibitors (PPI) do not further reduce the

168 de concomitant nonbismuth quadruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazol

169 ons have been demonstrated with misoprostol, proton pump inhibitors (PPIs) (only documented in high-r

170 n open-label crossover trial to test whether proton pump inhibitors (PPIs) affect the gastrointestina

171 20 under medical treatment with 40 mg/day of proton pump inhibitors (PPIs) and 25 after Nissen fundop

172 eported on the effects of concomitant use of proton pump inhibitors (PPIs) and dual antiplatelet ther

173 Proton pump inhibitors (PPIs) and histamine 2 receptor a

174 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor a

175 Proton pump inhibitors (PPIs) and histamine-2 receptor a

176 The association between proton pump inhibitors (PPIs) and nontyphoid salmonellos

177 Proton pump inhibitors (PPIs) are among the most common

178 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly used medicati

179 Proton pump inhibitors (PPIs) are covalent inhibitors of

180 Proton pump inhibitors (PPIs) are gastric acid-suppressi

181 Proton pump inhibitors (PPIs) are popular drugs for gast

182 Proton pump inhibitors (PPIs) are widely used for the tr

183 Proton pump inhibitors (PPIs) are widely used to treat g

184 bition of gastric acid secretion provided by proton pump inhibitors (PPIs) as compared with histamine

185 an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of

186 reflux esophagitis successfully treated with proton pump inhibitors (PPIs) began 24-hour esophageal p

187 ed RR of UGIB associated with current use of proton pump inhibitors (PPIs) for more than 1 month was

188 lux disease (GERD) who are not responding to proton pump inhibitors (PPIs) given once daily are very

189 Use of proton pump inhibitors (PPIs) has been associated with e

190 Proton pump inhibitors (PPIs) have been known to induce

191 Safety issues associated with proton pump inhibitors (PPIs) have recently attracted wi

192 Certain proton pump inhibitors (PPIs) interfere with clopidogrel

193 Proton pump inhibitors (PPIs) may be a risk factor for h

194 Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for

195 Proton pump inhibitors (PPIs) may interfere with calcium

196 Proton pump inhibitors (PPIs) might reduce the risk of s

197 study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state pharma

198 res (controls), prescription data for use of proton pump inhibitors (PPIs) or histamine-2 receptor an

199 was use of acid suppression medication with proton pump inhibitors (PPIs) or histamine-2 receptor an

200 omes in patients who were taking concomitant proton pump inhibitors (PPIs) or low-dose aspirin.

201 Proton pump inhibitors (PPIs) predispose to bacterial ov

202 ncreasing incidence of chronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secret

203 Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebo

204 e of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear.

205 Adding proton pump inhibitors (PPIs) to endoscopic therapy has

206 ients whose GERD symptoms were alleviated by proton pump inhibitors (PPIs) were recruited from outpat

207 ross-sectional study, 8.5% of patients using proton pump inhibitors (PPIs) were rectal carriers of ex

208 monary disease (COPD), ulcer history, use of proton pump inhibitors (PPIs), aspirin, nonsteroidal ant

209 y of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may hav

210 Proton pump inhibitors (PPIs), drugs that are widely use

211 e the risks associated with long-term use of proton pump inhibitors (PPIs), focusing on long-term use

212 Proton pump inhibitors (PPIs), frequently prescribed to

213 view summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional def

214 cid-reducing agents, such as H2 blockers and proton pump inhibitors (PPIs), remains a controversial r

215 etween the available antiplatelet agents and proton pump inhibitors (PPIs).

216 f this association is modulated by intake of proton pump inhibitors (PPIs).

217 s with IPF placed on antacid therapy such as proton pump inhibitors (PPIs).

218 Proton-pump inhibitors (PPIs) and clopidogrel are freque

219 Proton-pump inhibitors (PPIs) are believed to decrease t

220 Proton-pump inhibitors (PPIs) are often prescribed in co

221 Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for

222 Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointest

223 f Gastrointestinal Events Trial) showed that proton-pump inhibitors (PPIs) safely reduced rates of ga

224 All known proton pump inhibitors, PPIs, form a disulfide bond with

225 Here, we show that proton pump inhibitors promote progression of alcoholic

226 Patients (18-50 years) with proton pump inhibitor-resistant esophageal eosinophilia

227 causes of esophageal eosinophilia, including proton-pump inhibitor responsive esophageal eosinophilia

228 role of gastroesophageal reflux disease and proton pump inhibitor-responsive esophageal eosinophilia

229 causes of esophageal eosinophilia, including proton pump inhibitor-responsive esophageal eosinophilia

230 Proton-pump inhibitor-responsive esophageal eosinophilia

231 tamine receptor-2 antagonist and $7,802 with proton pump inhibitor, resulting in a cost saving of $1,

232 In critically ill patients, proton pump inhibitors seem to be more effective than hi

233 d cancer in H. felis/INS-GAS mice, while the proton pump inhibitor showed no such effects.

234 itis and allergies, twice-daily therapy with proton pump inhibitors significantly improved symptoms a

235 Omeprazole, an intravenous proton pump inhibitor, significantly reduced the rate of

236 Proton pump inhibitor single therapy did not significant

237 g methods, enhancing antibiotic and possibly proton pump inhibitor stewardship, and prescribing proph

238 The proton pump inhibitor test has been formally described a

239 The introduction of the proton pump inhibitor test, a highly sensitive and cost-

240 For patients with positive proton-pump-inhibitor test results, long-term treatment

241 ower response rates to acid suppression with proton pump inhibitors than do patients with endoscopy-p

242 the intralysosomal pH, since ionophores and proton pump inhibitors that dissipate the lysosomal pH g

243 that were either treated with omeprazole, a proton-pump inhibitor that suppresses acid secretion in

244 cy as the positive control of free drug plus proton pump inhibitor, the micromotors can function with

245 group and 31% of the control group chose the proton-pump inhibitor, the superior drug (P < 0.001).

246 cal trial, patients who received intravenous proton pump inhibitor therapy after endoscopic intervent

247 The relationship between proton pump inhibitor therapy and other acid suppressing

248 agement considerations (potential indefinite proton pump inhibitor therapy and/or surveillance endosc

249 Long-term proton pump inhibitor therapy at a regular dose is not a

250 tly weakly acidic reflux despite twice-daily proton pump inhibitor therapy before RFA increases the i

251 Chronic acid suppression by proton pump inhibitor therapy can lead to hypergastrinem

252 vement in GERD symptoms, quality of life and proton pump inhibitor therapy elimination after radiofre

253 ce costs with survival benefit comparable to proton pump inhibitor therapy for stress ulcer prophylax

254 Nocturnal acid breakthrough during proton pump inhibitor therapy has emerged as an importan

255 We investigated whether proton pump inhibitor therapy improved symptoms in patie

256 vironment created by surgical gastrectomy or proton pump inhibitor therapy in combination with a high

257 ibiotics are effective; notably, intravenous proton pump inhibitor therapy in lieu of vasoconstrictor

258 imal acid suppression (twice daily dosing of proton pump inhibitor therapy) in 8-12 weeks.

259 ase and this can be effectively treated with proton pump inhibitor therapy.

260 of interest was > or =5 years of cumulative proton pump inhibitor therapy.

261 ression of the Barrett segment compared with proton pump inhibitor therapy.

262 Proton-pump inhibitor therapy started within the past 30

263 rosive esophagitis after a 2-month course of proton-pump inhibitor therapy to assess healing and rule

264 apeutic trial of 4 to 8 weeks of twice-daily proton-pump inhibitor therapy.

265 Proton pump inhibitors, thyroid hormones, and dihydropyr

266 atients would need to receive an intravenous proton pump inhibitor to avoid one episode of rebleeding

267 d controlled parallel group trials comparing proton pump inhibitors to histamine 2 receptor antagonis

268 ated to prove the superiority of intravenous proton pump inhibitors to intravenous histamine-2-recept

269 The ability of proton pump inhibitors to prevent stress-related mucosal

270 ions of histamine-2-receptor antagonists and proton pump inhibitors to raise and maintain intragastri

271 osal eosinophil count, age, sex, and current proton pump inhibitor treatment did not predict this lim

272 (Use of high dose proton pump inhibitor treatment or normal pH monitoring)

273 et agents, had a medical condition requiring proton pump inhibitor treatment, or had already received

274 24-hour impedance-pH testing; they received proton pump inhibitors twice daily.

275 A retrospective cohort of proton-pump inhibitor-unresponsive, non-glucocorticoid-t

276 cular disease (HR, 1.95; 95% CI, 1.14-3.33), proton pump inhibitor use (HR, 1.87; 95% CI, 1.54-2.27),

277 additional recommendations by the panel were proton pump inhibitor use as a risk factor and the use o

278 Proton pump inhibitor use increases the risk of developi

279 rectal cancer, we examined whether long-term proton pump inhibitor use is associated with an increase

280 Modification of proton pump inhibitor use may increase rates of SVR.

281 Proton pump inhibitor use was associated with higher pla

282 Manometric changes, pH testing, and proton pump inhibitor use were assessed preoperatively a

283 tinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and

284 included Model for End-Stage Liver Disease, proton pump inhibitor use, and lower length of stay (c-s

285 on exists between C. difficile infection and proton pump inhibitor use.

286 orted in the pediatric age range linked with proton pump inhibitor use.

287 g/dL), absence of cirrhosis, and absence of proton pump inhibitor use.

288 y significant risk was demonstrated only for proton-pump inhibitor use.

289 Omeprazole is a proton pump inhibitor used in the treatment of peptic ul

290 Among high-dose proton pump inhibitor users (ie, > or =1.5 defined daily

291 meta-analyzed five trials (604 patients) of proton pump inhibitors versus placebo; there was no stat

292 Proton pump inhibitors were more effective than histamin

293 H2RAs compared with proton pump inhibitors were not significantly different

294 treated with intravenous corticosteroids and proton pump inhibitors were randomly assigned to one 30-

295 Proton pump inhibitors were stopped at least 7 days befo

296 No proton-pump inhibitors were administered during follow-u

297 om the ER in the presence of protonophore or proton pump inhibitors which increase the pH of intracel

298 ephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval.

299 These findings suggest that coprescribing a proton pump inhibitor with an NSAID is as effective as u

300 ay of medical therapy for GERD is the use of proton pump inhibitors, with as yet no superiority of an